COMMUNIQUÉS West-GlobeNewswire

Obalon Announces Second Quarter 2018 Financial Results
02/08/2018
SAN DIEGO, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon [...]
Aptinyx Initiates Phase 1 Study of NYX-458
02/08/2018
Development in Parkinson’s Disease Cognitive Impairment Planned EVANSTON, Ill., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative [...]
Photocure ASA: Presentation of the second quarter and first half year 2018 results
02/08/2018
Photocure will present its second quarter and first half year report on Wednesday 8 August 2018 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives from the company will be [...]
Shire plc : Rule 2.9 Announcement
02/08/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 2 August 2018 [...]
Press Release: Terveystalo sells its Riga based subsidiary Ava Clinic
02/08/2018
On 31 July 2018, Terveystalo Group has entered into an agreement with Eugin Group, Europe's second largest group fully dedicated to human reproduction, whereby Terveystalo sells to Eugin Group the entire operation of [...]
Nicox Initiates Phase 2 Study of NCX 470 in Open-Angle Glaucoma and Ocular
02/08/2018
Press Release Nicox Initiates Phase 2 Study of NCX 470 in Open-Angle Glaucoma and Ocular Hypertension ................................................. Study to randomize 420 patients in clinical sites across the U.S. [...]
Nicox : Initiation d'une étude de phase 2 pour le NCX 470 dans le glaucome à angle ouvert et l'hypertension oculaire
02/08/2018
Communiqué de presse Nicox : Initiation d'une étude de phase 2 pour le NCX 470 dans le glaucome à angle ouvert et l'hypertension oculaire ................................................. Etude randomisée sur 420 [...]
VALNEVA Delivers Strong IXIARO® Sales Growth and reports Further Progress on Key R&D Programs in H1
02/08/2018
Valneva Delivers Strong IXIARO ® Sales Growth and r eports Further Progress on Key R&D Programs in H1 Double-digit sales growth driven by IXIARO ® Product sales of €53.5 million in H1 2018, representing 11.4% year [...]
VALNEVA publie une forte croissance des ventes d'IXIARO® et avance sur ses programmes R&D clés au S1
02/08/2018
Valneva publie une forte croissance des ventes d'IXIARO ® et avance sur ses programmes R&D clés au S1 Croissance à deux chiffres des ventes soutenue par IXIARO ® Ventes de produits de €53,5 millions au S1 2018, [...]
argenx reports second quarter business update and half-year 2018 financial results
02/08/2018
Management to host conference call today at 3 p.m. CEST / 9 a.m. EDT August 2, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a [...]
BioCryst Pharmaceuticals Prices Public Offering of Common Stock
02/08/2018
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock, [...]
Precision Therapeutics Receives Approval of Delisting Request from German Stock Exchange
02/08/2018
MINNEAPOLIS, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery [...]
La Jolla Pharmaceutical Company to Release Second Quarter 2018 Financial Results and Host a Webcasted Conference Call on August 8, 2018
01/08/2018
SAN DIEGO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve [...]
FibroGen to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018
01/08/2018
Conference Call and Audio Webcast Scheduled for 5:00 p.m. ET (2:00 p.m. PT) SAN FRANCISCO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today announced that it will [...]
Intuitive Appoints Don Kania, Ph.D. to its Board of Directors
01/08/2018
SUNNYVALE, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (Nasdaq:ISRG), the pioneer and a global technology leader in robotic-assisted, minimally invasive surgery, today announced the appointment of [...]
Denali Therapeutics Announces Positive Clinical Results From LRRK2 Inhibitor Program for Parkinson’s Disease
01/08/2018
Healthy volunteer study of DNL201 meets all objectives in phase 1 clinical study, including CSF exposure levels and LRRK2 inhibition, as well as pathway engagement, at doses that were safe and well tolerated DNL201 will [...]
MyoKardia to Report Second Quarter 2018 Financial Results on Wednesday, August 8, 2018
01/08/2018
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable [...]
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01/08/2018
EMERYVILLE, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it [...]
AxoGen, Inc. Reports 2018 Second Quarter Financial Results
01/08/2018
Q2 Revenue of $20.6 million, representing 36% growth over prior year; reiterates full year 2018 guidance ALACHUA, Fla., Aug. 01, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and [...]

Pages